<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Malar J</journal-id><journal-title-group><journal-title>Malaria Journal</journal-title></journal-title-group><issn pub-type="epub">1475-2875</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1475-2875-8-286</article-id><article-id pub-id-type="pmid">20003246</article-id><article-id pub-id-type="doi">10.1186/1475-2875-8-286</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title><italic>IL4</italic> gene polymorphism and previous malaria experiences manipulate anti-<italic>Plasmodium falciparum </italic>antibody isotype profiles in complicated and uncomplicated malaria</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Tangteerawatana</surname><given-names>Piyatida</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>piyatida@swu.ac.th</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Perlmann</surname><given-names>Hedvig</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>hedvig.perlmann@imun.su.se</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Hayano</surname><given-names>Masashi</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>masashi@imun.su.se</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Kalambaheti</surname><given-names>Thareerat</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tmtkl@mahidol.ac.th</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Troye-Blomberg</surname><given-names>Marita</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>marita@imun.su.se</email></contrib><contrib contrib-type="author" corresp="yes" id="A6"><name><surname>Khusmith</surname><given-names>Srisin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tmskm@mahidol.ac.th</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand</aff><aff id="I2"><label>2</label>Department of Microbiology, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand</aff><aff id="I3"><label>3</label>Department of Immunology, Wenner-Gren Institute, Stockholm University, Stockholm, Sweden</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>10</day><month>12</month><year>2009</year></pub-date><volume>8</volume><fpage>286</fpage><lpage>286</lpage><history><date date-type="received"><day>19</day><month>7</month><year>2009</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Tangteerawatana et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Tangteerawatana et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.malariajournal.com/content/8/1/286"/><abstract><sec><title>Background</title><p>The <italic>IL4</italic>-590 gene polymorphism has been shown to be associated with elevated levels of anti-<italic>Plasmodium falciparum </italic>IgG antibodies and parasite intensity in the malaria protected Fulani of West Africa. This study aimed to investigate the possible impact of <italic>IL4</italic>-590C/T polymorphism on anti-<italic>P. falciparum </italic>IgG subclasses and IgE antibodies levels and the alteration of malaria severity in complicated and uncomplicated malaria patients with or without previous malaria experiences.</p></sec><sec><title>Methods</title><p>Anti-<italic>P.falciparum </italic>IgG subclasses and IgE antibodies in plasma of complicated and uncomplicated malaria patients with or without previous malaria experiences were analysed using ELISA. <italic>IL4</italic>-590 polymorphisms were genotyped using RFLP-PCR. Statistical analyses of the IgG subclass levels were done by Oneway ANOVA. Genotype differences were tested by Chi-squared test.</p></sec><sec><title>Results</title><p>The <italic>IL4</italic>-590T allele was significantly associated with anti-<italic>P. falciparum </italic>IgG3 antibody levels in patients with complicated (<italic>P </italic>= 0.031), but not with uncomplicated malaria (<italic>P </italic>= 0.622). Complicated malaria patients with previous malaria experiences carrying <italic>IL4</italic>-590TT genotype had significantly lower levels of anti-<italic>P. falciparum </italic>IgG3 (<italic>P </italic>= 0.0156), while uncomplicated malaria patients with previous malaria experiences carrying the same genotype had significantly higher levels <italic>(P </italic>= 0.0206) compared to their <italic>IL4</italic>-590 counterparts. The different anti-<italic>P. falciparum </italic>IgG1 and IgG3 levels among IL4 genotypes were observed. Complicated malaria patients with previous malaria experiences tended to have lower IgG3 levels in individuals carrying TT when compared to CT genotypes (<italic>P </italic>= 0.075). In contrast, complicated malaria patients without previous malaria experiences carrying CC genotype had significantly higher anti-<italic>P. falciparum </italic>IgG1 than those carrying either CT or TT genotypes (<italic>P </italic>= 0.004, <italic>P </italic>= 0.002, respectively).</p></sec><sec><title>Conclusion</title><p>The results suggest that <italic>IL4</italic>-590C or T alleles participated differently in the regulation of anti-malarial antibody isotype profiles in primary and secondary malaria infection and, therefore, could play an important role in alteration of malaria severity.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Anti-<italic>Plasmodium falciparum </italic>specific antibodies play a critical role in immune protection against asexual blood stages of the parasite, in which anti-<italic>P. falciparum </italic>IgG antibodies involved in reducing severity of the disease [<xref ref-type="bibr" rid="B1">1</xref>]. In particular, the cytophilic IgG1 and IgG3 subclasses are considered to protect against <italic>P. falciparum</italic>, whereas IgG2 and IgM are not, and even suggested to block protective effects of the former Ig subclasses [<xref ref-type="bibr" rid="B2">2</xref>]. Anti-<italic>P. falciparum </italic>IgE, as well as total IgE antibodies, which are elevated in individuals exposed to malaria in Thailand, have been implicated to play a pathogenic role during malaria infection [<xref ref-type="bibr" rid="B1">1</xref>]. In contrast, the anti-<italic>P. falciparum </italic>IgE levels in asymptomatic individuals in Tanzania were associated with a reduced risk for subsequent malaria disease [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>The regulation of antibody profiles in patients with complicated and uncomplicated malaria is still largely unknown. In both human and mice, different cytokines are thought to induce particular Ig isotypes. In humans, IL4 regulates B cells to express the &#x003b3;1, &#x003b3;2, &#x003b3;3, &#x003b3;4, &#x003b1;1, &#x003b1;2 and &#x003b5;, germline gene transcripts (GLT) and to secrete the corresponding proteins [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. IL10 promotes isotype switching from IgM to IgG1, IgG3, IgG4 and/or IgE [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>] while IFN-&#x003b3; promotes IgG2 [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. The inter-individual variation in cytokine production may be reflected by polymorphisms in regulatory region of the corresponding genes. The <italic>IL4</italic>-590 C/T transition in <italic>IL4 </italic>promoter was shown to influence the IL4 production as well as the elevated levels of total IgE [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. The <italic>IL4</italic>-590T allele corresponded to <italic>IL4</italic>-524T and <italic>IL4</italic>-589T alleles in an alternative numbering scheme [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. In the Fulani tribe in West Africa, <italic>IL4</italic>-524T allele was found to be associated with the elevated levels of anti-<italic>P. falciparum </italic>IgG antibodies and protection against malaria [<xref ref-type="bibr" rid="B14">14</xref>], while <italic>IL4</italic>-589T allele was associated with the elevated levels of total IgE in children with severe malaria living in Burkina Faso [<xref ref-type="bibr" rid="B15">15</xref>]. Conversely, total IgE levels were significantly elevated in children with cerebral malaria who carried <italic>IL4</italic>-590T allele and have been living in Ghana [<xref ref-type="bibr" rid="B16">16</xref>]. Thus, the role of <italic>IL4</italic>-590T allele in regulating antibody profiles and malaria severity is controversial. In mice infected with <italic>Plasmodium chabaudi chabaudi</italic>, the specific IgG2a and IgG3 antibodies are predominant in primary polyclonal B cell activation. At that point, IFN-&#x003b3; is markedly stimulated, while IL4 is moderately enhanced. In secondary IgG1-restricted response, only IL4 is produced [<xref ref-type="bibr" rid="B17">17</xref>]. According to previous findings, the <italic>IL4</italic>-590 C/T polymorphism influences the balance between IL4 and IFN-&#x003b3; and thus, could alter the severity of malaria [<xref ref-type="bibr" rid="B18">18</xref>]. When the same sets of sera were used subsequently to determine the anti-<italic>P. falciparum </italic>IgG subclasses and IgE antibodies, the results showed different regulation in patients with complicated and uncomplicated malaria [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>Therefore, it is of interest to evaluate the impact of <italic>IL4</italic>-590 C/T single nucleotide polymorphism (SNP) on the production of anti-<italic>P. falciparum </italic>-IgG1, -IgG2, -IgG3, IgE antibodies and to determine whether such polymorphism and specific antibodies levels were associated with previous malaria experiences and clinical outcome of the disease in people living in a malaria endemic areas in Thailand.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Malaria subjects</title><p>The same sets of patients previously reported were studied [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. Briefly, 110 and 169 patients with complicated (CM) and uncomplicated malaria (UCM), respectively, who had been living at Thai-Myanmar border in the west and Thai-Cambodia border in the east of Thailand; where malaria is endemic; were enrolled. These areas are considered as having low and seasonal malaria transmission. The annual malaria incidence rates in 2001 were 2 to 6/1,000 population [<xref ref-type="bibr" rid="B20">20</xref>]. The two groups of patients were matched for age (<italic>P </italic>= 0.849), gender (<italic>P </italic>= 0.137) and nationality, <italic>i.e </italic>Thai, Burmese, Mon and Karen (<italic>P </italic>= 0.614). The median age was 25 years (ranged 14-67) for complicated and 24 years (ranged 13-65) for uncomplicated malaria. Based on the interview and clinical records, 27.3% of patients with complicated and 55% of those with uncomplicated malaria had previous malaria experiences. The number of previous malaria episodes in these patients varied widely, describing mostly 1-2 episodes of malaria (84/125), 3-8 episodes (27/125) and many episodes (12/125). However, the duration of malaria infection upon admission and the previous malaria episodes among patients were far different, varying from one month to more than 10 years (mostly between one month and two years). However, both groups of patients had acute malaria infection upon admission. Therefore, complicated malaria patients with or without previous malaria experiences (CME, CMN, respectively) and uncomplicated malaria patients with or without previous malaria experiences (UCME, UCMN, respectively) were identified. Clinical manifestations of complicated and uncomplicated malaria were defined according to World Health Organization criteria [<xref ref-type="bibr" rid="B21">21</xref>]. Cerebral malaria was defined as unrousable coma with positive asexual forms of <italic>P. falciparum </italic>in blood smears, while other causes of coma were excluded. Severe malaria but not cerebral (non-cerebral severe malaria) was defined as patients exhibiting one or more of the following signs, hyperparasitaemia (&#x0003e;250,000 parasite/ml), hypoglycaemia (glucose &#x0003c;22 nmol/l), severe anaemia (haematocrit &#x0003c;20% or haemoglobin &#x0003c;7.0 g/d) or increased serum level of creatinine more than 3.0 mg/dl. The patients with complicated malaria comprised of all severe forms including cerebral malaria. Uncomplicated malaria was characterized by a positive blood smear and fever without other causes of infections and no manifestations of severe malaria as described. The patients were transported for admission to the Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok. The study has been ethically approved by the Institute Review Board of the Faculty of Tropical Medicine, Mahidol University, Bangkok and the fully informed consent was obtained from all patients. Other details about the patients are delineated in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of complicated and uncomplicated malaria patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="center">Complicated<break/>malaria (110)<sup>a</sup></th><th align="center">Uncomplicated<break/>malaria (169)<sup>a</sup></th><th align="center"><italic>P</italic>-value<sup>b</sup></th></tr></thead><tbody><tr><td align="left">Age<sup>c</sup>(range)</td><td align="center">25.0 (14-67)</td><td align="center">24.0 (13-65)</td><td align="center">0.849</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Sex (male/female)</td><td align="center">75/35</td><td align="center">133/36</td><td align="center">0.137</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Nationality<sup>d</sup></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Burmese</td><td align="center">17 (15.5)</td><td align="center">24 (14.2)</td><td align="center">0.614</td></tr><tr><td align="left">&#x02003;Karen</td><td align="center">18 (16.4)</td><td align="center">27 (16.0)</td><td/></tr><tr><td align="left">&#x02003;Mon</td><td align="center">37 (33.6)</td><td align="center">72 (42.6)</td><td/></tr><tr><td align="left">&#x02003;Thai</td><td align="center">38 (34.5)</td><td align="center">45 (26.6)</td><td/></tr><tr><td align="left">&#x02003;Laos</td><td align="center">0</td><td align="center">1 (0.6)</td><td/></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Blood groups<sup>d</sup></td><td/><td/><td/></tr><tr><td align="left">&#x02003;A</td><td align="center">21 (19.1)</td><td align="center">27 (16.0)</td><td align="center">0.556</td></tr><tr><td align="left">&#x02003;AB</td><td align="center">6 (5.5)</td><td align="center">7 (4.1)</td><td/></tr><tr><td align="left">&#x02003;B</td><td align="center">34 (30.9)</td><td align="center">58 (34.3)</td><td/></tr><tr><td align="left">&#x02003;O</td><td align="center">47 (42.7)</td><td align="center">66 (39.1)</td><td/></tr><tr><td align="left">&#x02003;NR</td><td align="center">2 (1.8)</td><td align="center">11 (6.5)</td><td/></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Haemoglobin variants*<sup>d</sup></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Hb variants</td><td align="center">14 (12.7)</td><td align="center">29 (17.2)</td><td align="center">0.825</td></tr><tr><td align="left">&#x02003;Normal</td><td align="center">95 (86.4)</td><td align="center">133 (78.7)</td><td/></tr><tr><td align="left">&#x02003;NR</td><td align="center">1 (0.9)</td><td align="center">7 (4.1)</td><td/></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">G6PD deficiency<sup>d</sup></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Deficiency</td><td align="center">13 (11.8)</td><td align="center">14 (8.3)</td><td align="center">0.597</td></tr><tr><td align="left">&#x02003;Normal</td><td align="center">96 (87.3)</td><td align="center">153 (90.5)</td><td/></tr><tr><td align="left">&#x02003;NR</td><td align="center">1 (0.9)</td><td align="center">2 (1.2)</td><td/></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Parasitaemia<sup>e </sup>(range)</td><td align="center">117 322 (33-1 336 900)</td><td align="center">5641 (17-238 800)</td><td align="center">&#x0003c;0.0001</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Highest fever&#x000b0;C<sup>f</sup></td><td align="center">38.1 &#x000b1; 1.005</td><td align="center">38.4 &#x000b1; 0.981</td><td align="center">0.011</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Haemoglobin g/d<sup>f</sup></td><td align="center">11.4 &#x000b1; 0.24</td><td align="center">12.1 &#x000b1; 0.17</td><td align="center">0.021</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Creatinine mg/dl<sup>f</sup></td><td align="center">1.36 &#x000b1; 1.21</td><td align="center">0.88 &#x000b1; 0.37</td><td align="center">&#x0003c;0.0001</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Glucose nmol/l<sup>f</sup></td><td align="center">131.47 &#x000b1; 62.06</td><td align="center">118.17 &#x000b1; 28.78</td><td align="center">0.016</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Splenomegaly<sup>g</sup></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Positive</td><td align="center">18 (16.4)</td><td align="center">3 (1.8)</td><td align="center">0.039</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">92 (83.4)</td><td align="center">166 (98.2)</td><td/></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Hepatomegaly<sup>g</sup></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Positive</td><td align="center">66 (60)</td><td align="center">32 (18.9)</td><td align="center">&#x0003c; 0.0001</td></tr><tr><td align="left">&#x02003;Negative</td><td align="center">44 (40)</td><td align="center">137 (81.1)</td><td/></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">Previous malaria episodes<sup>d</sup></td><td/><td/><td/></tr><tr><td align="left">&#x02003;Yes</td><td align="center">30 (27.3)</td><td align="center">93 (55.0)</td><td align="center">&#x0003c; 0.0004</td></tr><tr><td align="left">&#x02003;No</td><td align="center">78 (70.9)</td><td align="center">76 (45)</td><td/></tr><tr><td align="left">&#x02003;NR</td><td align="center">2 (1.8)</td><td align="center">0</td><td/></tr></tbody></table><table-wrap-foot><p>a = Number of patients, b = Mann Whitney <italic>U </italic>or unpaired <italic>t </italic>test used for the analysis, c = Median, d = Percentages (in the parenthesis), e = Geometric mean/ml of blood, f = Mean &#x000b1; SD, g = Percentages of individual with enlarged spleens and/or liver are in the parenthesis. *The Hemoglobin (Hb) variants includes HbE, HbF. NR = No report.</p></table-wrap-foot></table-wrap></sec><sec><title>Blood samples</title><p>Blood samples from patients with complicated and uncomplicated malaria were collected in EDTA sterile tubes before treatment on admission. The plasma and packed cells were separated and frozen at -20&#x000b0;C until use.</p></sec><sec><title>Microscopic examination</title><p>Thick and thin films were made for microscopic examination after standard Giemsa staining. Parasite densities were determined by calculating <italic>P. falciparum </italic>parasites per ml of blood obtained from the number of parasites observed per 1,000 erythrocytes in thin film or per 200 leucocytes in thick film.</p></sec><sec><title>Malaria antigens</title><p>The laboratory <italic>P. falciparum </italic>strain F32 was used to prepare the antigens for malaria antibodies detection. The late stages of <italic>P. falciparum </italic>infected erythrocytes were enriched by 60% Percoll and sonicated as described [<xref ref-type="bibr" rid="B22">22</xref>].</p></sec><sec><title>Detection of anti-<italic>P. falciparum </italic>IgG subclasses and IgE antibody levels</title><p>Anti-<italic>P. falciparum </italic>-IgG1, -IgG2, -IgG3 and IgE antibodies levels were determined by enzyme-linked immunosorbent assay (ELISA) as described previously [<xref ref-type="bibr" rid="B23">23</xref>] with some modification. The monoclonal antibodies used in the ELISA were given [<xref ref-type="bibr" rid="B19">19</xref>]. Negative control sera were from Swedish donors who have never been exposed to malaria.</p></sec><sec><title>Genotyping</title><p>DNA was extracted from buffy coats by phenol-chloroform extraction [<xref ref-type="bibr" rid="B24">24</xref>]. Genomic DNA was used as a template for amplification by PCR and <italic>IL4</italic>-590 C/T polymorphism was detected by restriction fragment length polymorphism analysis as previously described [<xref ref-type="bibr" rid="B18">18</xref>].</p></sec><sec><title>Statistical analyses</title><p>The data were analysed using SPSS or StatView computer software. The differences in characteristics of the patients with complicated and uncomplicated malaria were analyzed by unpaired <italic>t</italic>-test or Mann Whitney <italic>U </italic>test. The highest fever, haemoglobin, creatinine, and glucose levels between the two patient groups were tested by unpaired <italic>t</italic>-test, while the other characteristics were tested by Mann Whitney <italic>U </italic>test. The Chi-squared test was used to compare allele and genotype frequencies between the two patients groups. One-way ANOVA and unpaired <italic>t</italic>-test after log transformation were used to evaluate the significant associations between anti-<italic>P. falciparum </italic>IgG subclasses or IgE antibodies and the <italic>IL4</italic>-590 genotypes. The IgG subclasses and IgE were taken in the extreme 3 tiles. The genetic distribution of the <italic>IL4</italic>-590 genotypes between the low and high quartile was compared using Chi-squared test. A <italic>P</italic>-value of less than 0.05 was considered to be significant.</p></sec></sec><sec><title>Results</title><sec><title><italic>IL4</italic>-590 C/T allele frequency in complicated and uncomplicated malaria patients with or without previous malaria experiences</title><p>As described previously [<xref ref-type="bibr" rid="B19">19</xref>], the frequency of <italic>IL4</italic>-590 T allele in patients with complicated malaria did not differ from those with uncomplicated malaria (0.72 in both groups). When the allele and genotype frequencies in patients with or without previous malaria experiences were explored, the allele and genotype frequencies between complicated and uncomplicated malaria groups either with or without previous malaria experiences did not differed (<italic>P</italic>-value allele: 0.7501 <italic>vs </italic>0.8755 and genotype: 0.9137 <italic>vs </italic>0.9459 for patients with or without previous malaria experiences, respectively) (Table <xref ref-type="table" rid="T2">2</xref>)</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Allele and genotype frequencies of <italic>IL4</italic>-590 polymorphism in complicated and uncomplicated malaria patients with or without previous malaria experiences.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><bold><italic>IL4</italic>-590 C/T</bold></td><td align="center" colspan="3"><bold>Genotype n (%)</bold></td><td align="center" colspan="2"><bold>Allele %</bold></td></tr><tr><td/><td colspan="3"><hr/></td><td colspan="2"><hr/></td></tr><tr><td/><td align="center"><bold>CC</bold></td><td align="center"><bold>CT</bold></td><td align="center"><bold>CC</bold></td><td align="center"><bold>C</bold></td><td align="center"><bold>T</bold></td></tr><tr><td colspan="4"><hr/></td><td colspan="2"><hr/></td></tr><tr><td align="left">CME</td><td align="center">2 (7.4)</td><td align="center">11 (40.7)</td><td align="center">14 (51.9)</td><td align="center">27.78</td><td align="center">72.22</td></tr><tr><td align="left">UCME</td><td align="center">7 (7.7)</td><td align="center">33 (36.2)</td><td align="center">51 (56.0)</td><td align="center">25.82</td><td align="center">74.18</td></tr><tr><td align="left"><italic>P</italic>-value<sup>#</sup></td><td/><td align="center">0.9137</td><td/><td align="center">0.7501</td><td/></tr><tr><td colspan="4"><hr/></td><td colspan="2"><hr/></td></tr><tr><td align="left">CMN</td><td align="center">4 (5.3)</td><td align="center">34 (44.7)</td><td align="center">38 (50.0)</td><td align="center">27.63</td><td align="center">72.37</td></tr><tr><td align="left">UCMN</td><td align="center">4 (5.4)</td><td align="center">35 (47.3)</td><td align="center">35 (47.3)</td><td align="center">29.05</td><td align="center">70.95</td></tr><tr><td align="left"><italic>P</italic>-value</td><td/><td align="center">0.9459</td><td/><td align="center">0.8755</td><td/></tr></tbody></table><table-wrap-foot><p><sup>#</sup>Chi- squared test was used for the analysis</p></table-wrap-foot></table-wrap></sec><sec><title>Association between <italic>IL4</italic>-590 polymorphism and anti-<italic>P. falciparum </italic>IgG subclasses and IgE antibody levels</title><p>The anti -<italic>P. falciparum </italic>-IgG1, -IgG2, -IgG3 and IgE antibody concentrations in relation to <italic>IL4</italic>-590 genotypes in complicated malaria (CM) and uncomplicated malaria (UCM) patients are illustrated in Table <xref ref-type="table" rid="T3">3</xref>. In complicated malaria, the levels of anti-<italic>P. falciparum </italic>IgG3 were significantly different among individuals carrying <italic>IL4</italic>-590 TT, CT and CC genotypes (<italic>P </italic>= 0.031), while the levels of anti-<italic>P. falciparum </italic>IgG1 tended to be significant among <italic>IL4</italic>-590 genotype (<italic>P </italic>= 0.095). To study the impact between <italic>IL4</italic>-590 genotypes on anti-<italic>P. falciparum </italic>IgG1 and IgG3 levels, the antibody levels in individuals carrying different genotypes were compared by TT to CT, TT to CC and CT to CC genotypes. As shown in Table <xref ref-type="table" rid="T4">4</xref>, the anti-<italic>P. falciparum </italic>IgG1 levels were significantly different between individuals carrying TT genotype compared to those carrying CC genotype (median 18.04 <italic>vs </italic>223.80: <italic>P </italic>= 0.025) and between individuals carrying CT genotype compared to those carrying CC genotype (median 24.12 <italic>vs </italic>223.80, <italic>P </italic>= 0.037). In contrast, the anti-<italic>P.falciparum </italic>IgG3 levels were significantly different only between individuals carrying TT compared to those carrying CT genotype (median 0.51 <italic>vs </italic>1.20, <italic>P </italic>= 0.030). When complicated malaria patients with or without previous malaria experiences (CME and CMN, respectively) were analysed separately, similar patterns were seen by the anti-<italic>P. falciparum </italic>IgG1 levels were significantly different between individuals carrying TT and CC genotypes (median 8.54 <italic>vs </italic>223.80: <italic>P </italic>= 0.002) as well as between CT and CC genotypes (median 13.94 <italic>vs </italic>223.80: <italic>P </italic>= 0.004). Interestingly, these observations were seen only in complicated malaria patients without previous malaria experiences. While the difference in anti-<italic>P. falciparum </italic>IgG3 levels between patients carrying TT and CT genotype tended to be significant in complicated malaria patients with previous malaria experiences (median 1.32 <italic>vs </italic>5.62: <italic>P </italic>= 0.075). No such tendency could be observed in the levels of anti-<italic>P. falciparum </italic>IgG2 and IgE in complicated malaria patients either with or without previous malaria experiences. Among uncomplicated malaria patients carrying TT, CT or CC genotypes, the levels of anti-<italic>P. falciparum</italic>-IgG1, -IgG2, -IgG3 and IgE did not differ.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Anti-<italic>P. falciparum </italic>IgG subclass and IgE levels (median) separated by <italic>IL4</italic>-590 CT genotype in patients with complicated and uncomplicated malaria (CM, UCM).</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th align="center" colspan="2">CC</th><th align="center" colspan="2">CT</th><th align="center" colspan="2">TT</th></tr><tr><th/><th colspan="7"><hr/></th></tr><tr><th/><th align="left">N</th><th align="center">Median</th><th align="center">N</th><th align="center">Median</th><th align="center">N</th><th align="center">Median</th><th align="center"><italic>P</italic>-value<sup>#</sup></th></tr></thead><tbody><tr><td align="left"><bold>CM</bold></td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG1*</td><td align="left">5</td><td align="center">223.80</td><td align="center">46</td><td align="center">24.12</td><td align="center">53</td><td align="center">18.04</td><td align="center"><bold>0.096</bold></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG2*</td><td align="left">5</td><td align="center">6.05</td><td align="center">46</td><td align="center">2.03</td><td align="center">53</td><td align="center">2.79</td><td align="center">0.112</td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG3*</td><td align="left">5</td><td align="center">1.51</td><td align="center">46</td><td align="center">1.20</td><td align="center">53</td><td align="center">1.52</td><td align="center"><bold>0.031</bold></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgE**</td><td align="left">5</td><td align="center">0.43</td><td align="center">47</td><td align="center">0.62</td><td align="center">53</td><td align="center">2.36</td><td align="center">0.915</td></tr><tr><td colspan="8"><hr/></td></tr><tr><td align="left"><bold>UCM</bold></td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG1*</td><td align="left">11</td><td align="center">252.80</td><td align="center">67</td><td align="center">39.32</td><td align="center">84</td><td align="center">88.21</td><td align="center">0.195</td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG2*</td><td align="left">11</td><td align="center">7.60</td><td align="center">68</td><td align="center">4.40</td><td align="center">83</td><td align="center">5.77</td><td align="center">0.299</td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG3*</td><td align="left">11</td><td align="center">2.65</td><td align="center">68</td><td align="center">2.69</td><td align="center">85</td><td align="center">3.13</td><td align="center">0.622</td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgE**</td><td align="left">11</td><td align="center">0.96</td><td align="center">68</td><td align="center">0.65</td><td align="center">85</td><td align="center">0.76</td><td align="center">0.892</td></tr></tbody></table><table-wrap-foot><p>* = &#x003bc;g/ml, ** = ng/ml, N = number of patients, <sup>#</sup>Statistical analysis of differences</p><p>in IgG subclass levels among the different genotypes tested with ANOVA.</p></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Anti-<italic>P. falciparum </italic>IgG1 and IgG3 levels (median) according to <italic>IL4</italic>-590 genotypes in complicated malaria patients with or without previous malaria experiences.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th align="center">CM</th><th/><th/></tr><tr><th/><th colspan="4"><hr/></th></tr><tr><th/><th align="center">CC (5)<sup>a</sup></th><th align="center">CT (46)<sup>a</sup></th><th align="center">TT (53)<sup>a</sup></th><th align="center"><italic>P</italic>-value<sup>#</sup></th></tr></thead><tbody><tr><td align="left">Anti-<italic>Pf</italic>IgG1*</td><td align="center">-</td><td align="center">24.12</td><td align="center">18.04</td><td align="center">0.628</td></tr><tr><td/><td align="center"><bold>223.80</bold></td><td align="center">-</td><td align="center"><bold>18.04</bold></td><td align="center"><bold>0.025</bold></td></tr><tr><td/><td align="center"><bold>223.80</bold></td><td align="center"><bold>24.12</bold></td><td align="center">-</td><td align="center"><bold>0.037</bold></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG3*</td><td align="center"><bold>-</bold></td><td align="center"><bold>1.20</bold></td><td align="center"><bold>0.51</bold></td><td align="center"><bold>0.030</bold></td></tr><tr><td/><td align="center">1.51</td><td align="center"><bold>-</bold></td><td align="center">0.51</td><td align="center">0.159</td></tr><tr><td/><td align="center">1.51</td><td align="center">1.20</td><td align="center"><bold>-</bold></td><td align="center">0.455</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td/><td/><td align="center"><bold>CME</bold></td><td/><td/></tr><tr><td/><td colspan="4"><hr/></td></tr><tr><td/><td align="center">CC (2)</td><td align="center">CT (11)</td><td align="center">TT (14)</td><td align="center"><italic>P</italic>-value</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG1*</td><td align="center"><bold>-</bold></td><td align="center">31.13</td><td align="center">53.04</td><td align="center">0.983</td></tr><tr><td/><td align="center">280.43</td><td align="center">-</td><td/><td align="center">0.835</td></tr><tr><td/><td align="center">280.43</td><td align="center">31.13</td><td align="center">53.04</td><td align="center">0.830</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG3*</td><td align="center"><bold>-</bold></td><td align="center"><bold>5.62</bold></td><td align="center"><bold>1.32</bold></td><td align="center"><bold>0.075</bold></td></tr><tr><td/><td align="center">8.06</td><td align="center"><bold>-</bold></td><td align="center">1.32</td><td align="center">0.384</td></tr><tr><td/><td align="center">8.06</td><td align="center">5.62</td><td align="center"><bold>-</bold></td><td align="center">0.961</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td/><td/><td align="center"><bold>CMN</bold></td><td/><td/></tr><tr><td/><td colspan="4"><hr/></td></tr><tr><td/><td align="center">CC (3)</td><td align="center">CT (33)</td><td align="center">TT (38)</td><td align="center"><italic>P</italic>-value</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG1*</td><td align="center"><bold>-</bold></td><td align="center">13.94</td><td align="center">8.54</td><td align="center">0.636</td></tr><tr><td/><td align="center"><bold>223.80</bold></td><td align="center">-</td><td align="center"><bold>8.54</bold></td><td align="center"><bold>0.002</bold></td></tr><tr><td/><td align="center"><bold>223.80</bold></td><td align="center"><bold>13.94</bold></td><td align="center">-</td><td align="center"><bold>0.004</bold></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG3*</td><td align="center"><bold>-</bold></td><td align="center">0.80</td><td align="center">0.40</td><td align="center">0.217</td></tr><tr><td/><td align="center">1.51</td><td align="center">-</td><td align="center">0.40</td><td align="center">0.154</td></tr><tr><td/><td align="center">1.51</td><td align="center">0.80</td><td align="center">-</td><td align="center">0.274</td></tr></tbody></table><table-wrap-foot><p>* = &#x003bc;g/ml, <sup>#</sup>Statistical analysis of differences in IgG subclass levels</p><p>between the different genotypes tested with unpaired <italic>t</italic>-test,</p><p>a = Number of patients (in the parenthesis).</p></table-wrap-foot></table-wrap><p>To investigate whether the anti-<italic>P. falciparum </italic>IgG subclasses and IgE were associated with certain <italic>IL4</italic>-590 genotypes and whether the distribution of the C and/or T allele differed between patients with complicated and uncomplicated malaria either with low or high specific antibody levels, the antibody profiles were divided into three tiles, <italic>i.e</italic>. those with low, medium and high antibody levels. This division was based on the findings that there was a great individual variation in antibody responses to the crude plasmodium antigens. Because of the low numbers of homozygotes for the <italic>IL4</italic>-590 C allele frequency, the individuals homozygous and heterozygous for C alleles (CC+CT) were pooled and compared with those homozygous for T alleles. In complicated malaria, individuals homozygous for T alleles had significantly lower anti-<italic>P. falciparum </italic>IgG3 antibody (<italic>P </italic>= 0.0054), while no significant difference was found in uncomplicated malaria (<italic>P </italic>= 0.079). Conversely, the <italic>IL4</italic>-590 genotypes were not significantly associated either with anti-<italic>P. falciparum </italic>-IgG1, -IgG2 or with anti-<italic>P. falciparum </italic>IgE antibodies when low and high tiles in complicated and uncomplicated malaria were compared (Table <xref ref-type="table" rid="T5">5</xref>). When the results were analysed separately according to the history of individual's malaria experiences, only individuals homozygous for T alleles had significantly lower anti-<italic>P. falciparum </italic>IgG3 antibody in complicated malaria patients with previous malaria experiences (CME) (<italic>P </italic>= 0.0156) while higher anti-<italic>P. falciparum </italic>IgG3 antibody levels were seen in uncomplicated malaria patients with previous malaria experiences (UCME) (<italic>P </italic>= 0.0206). In contrast, no such associations could be found when the <italic>IL4</italic>-590 genotypes were compared between complicated malaria patients without previous malaria experiences (CMN) and uncomplicated malaria patients. Conversely, high anti-<italic>P. falciparum </italic>IgG1 antibody levels seem to be associated with the <italic>IL4</italic>-590TT genotype in uncomplicated malaria patients with previous malaria experiences (UCME) (<italic>P </italic>= 0.1219) (Table <xref ref-type="table" rid="T6">6</xref>). No significant associations between <italic>IL4</italic>-590 genotypes and anti-<italic>P. falciparum </italic>IgG2 and IgE antibodies were found when the low and the high tiles were compared in all CME, CMN, UCME and UCMN (uncomplicated malaria patients without previous malaria experiences)</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Association between <italic>IL4</italic>-590 genotype and anti-<italic>P. falciparum </italic>-IgG1, -IgG2, -IgG3 and IgE low or high tiled levels in patients with complicated and uncomplicated malaria.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td/><td/><td/><td/><td align="center" colspan="3"><bold>Complicated</bold></td><td/><td align="center" colspan="3"><bold>Uncomplicated</bold></td><td/></tr><tr><td/><td/><td/><td/><td colspan="4"><hr/></td><td colspan="4"><hr/></td></tr><tr><td/><td align="left" colspan="2"><bold>3-tiles of Ig levels</bold></td><td align="left"><bold>N</bold></td><td align="center"><bold>CC</bold></td><td align="center"><bold>CT</bold></td><td align="center"><bold>TT</bold></td><td align="center"><bold><italic>P</italic>-value<sup>#</sup></bold></td><td align="center"><bold>CC</bold></td><td align="center"><bold>CT</bold></td><td align="center"><bold>TT</bold></td><td align="center"><bold><italic>P</italic>-value<sup>#</sup></bold></td></tr><tr><td colspan="8"><hr/></td><td colspan="4"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf </italic>IgG1</td><td/><td/><td align="left">274</td><td align="center">5<sup>A</sup></td><td align="center">46<sup>B</sup></td><td align="center">53<sup>C</sup></td><td/><td align="center">11<sup>A</sup></td><td align="center">67<sup>B</sup></td><td align="center">84<sup>C</sup></td><td/></tr><tr><td align="left">Anti-<italic>Pf </italic>IgG2</td><td/><td/><td align="left">274</td><td align="center">5</td><td align="center">46</td><td align="center">53</td><td/><td align="center">11</td><td align="center">68</td><td align="center">83</td><td/></tr><tr><td align="left">Anti-<italic>Pf </italic>IgG3</td><td/><td/><td align="left">276</td><td align="center">5</td><td align="center">46</td><td align="center">53</td><td/><td align="center">11</td><td align="center">68</td><td align="center">85</td><td/></tr><tr><td align="left">Anti-<italic>Pf </italic>IgE</td><td/><td/><td align="left">277</td><td align="center">5</td><td align="center">47</td><td align="center">53</td><td/><td align="center">11</td><td align="center">68</td><td align="center">85</td><td/></tr><tr><td colspan="8"><hr/></td><td colspan="4"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG1*</td><td align="left">Low</td><td align="left">0-14.47</td><td align="left">91<sup>D</sup></td><td align="center">0</td><td align="center">20</td><td align="center">26</td><td align="center">0.395</td><td align="center">2</td><td align="center">23</td><td align="center">16</td><td align="center">0.118</td></tr><tr><td/><td align="left">Medium</td><td align="left">14.76-106.1</td><td align="left">92</td><td align="center">2</td><td align="center">16</td><td align="center">16</td><td/><td align="center">3</td><td align="center">20</td><td align="center">32</td><td/></tr><tr><td/><td align="left">High</td><td align="left">107.2-1874</td><td align="left">91</td><td align="center">3</td><td align="center">10</td><td align="center">11</td><td/><td align="center">6</td><td align="center">24</td><td align="center">36</td><td/></tr><tr><td colspan="8"><hr/></td><td colspan="4"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG2*</td><td align="left">Low</td><td align="left">0.414-2.384</td><td align="left">91</td><td align="center">0</td><td align="center">26</td><td align="center">23</td><td align="center">0.856</td><td align="center">2</td><td align="center">23</td><td align="center">17</td><td align="center">0.179</td></tr><tr><td/><td align="left">Medium</td><td align="left">2.386-6.617</td><td align="left">92</td><td align="center">3</td><td align="center">12</td><td align="center">22</td><td/><td align="center">3</td><td align="center">19</td><td align="center">29</td><td/></tr><tr><td/><td align="left">High</td><td align="left">6.629-177</td><td align="left">91</td><td align="center">2</td><td align="center">8</td><td align="center">8</td><td/><td align="center">6</td><td align="center">26</td><td align="center">37</td><td/></tr><tr><td colspan="8"><hr/></td><td colspan="4"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG3*</td><td align="left">Low</td><td align="left">0.053-0.798</td><td align="left">92</td><td align="center"><bold>1</bold></td><td align="center"><bold>19</bold></td><td align="center"><bold>30</bold></td><td align="center"><bold>0.0054</bold></td><td align="center"><bold>3</bold></td><td align="center"><bold>20</bold></td><td align="center"><bold>16</bold></td><td align="center"><bold>0.079</bold></td></tr><tr><td/><td align="left">Medium</td><td align="left">0.854-3.55</td><td align="left">92</td><td align="center">2</td><td align="center">13</td><td align="center">18</td><td/><td align="center">5</td><td align="center">22</td><td align="center">28</td><td/></tr><tr><td/><td align="left">High</td><td align="left">3.629-119</td><td align="left">92</td><td align="center"><bold>2</bold></td><td align="center"><bold>14</bold></td><td align="center"><bold>5</bold></td><td/><td align="center"><bold>3</bold></td><td align="center"><bold>26</bold></td><td align="center"><bold>41</bold></td><td/></tr><tr><td colspan="8"><hr/></td><td colspan="4"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf </italic>IgE**</td><td align="left">Low</td><td align="left">0.015-0.3851</td><td align="left">92</td><td align="center">2</td><td align="center">15</td><td align="center">17</td><td align="center">0.896</td><td align="center">3</td><td align="center">28</td><td align="center">25</td><td align="center">0.564</td></tr><tr><td/><td align="left">Medium</td><td align="left">0.3854-1.332</td><td align="left">93</td><td align="center">2</td><td align="center">17</td><td align="center">21</td><td/><td align="center">4</td><td align="center">14</td><td align="center">30</td><td/></tr><tr><td/><td align="left">High</td><td align="left">1.346-29.05</td><td align="left">92</td><td align="center">1</td><td align="center">15</td><td align="center">15</td><td/><td align="center">4</td><td align="center">26</td><td align="center">30</td><td/></tr></tbody></table><table-wrap-foot><p>N = Number of plasma for determining IgG1, IgG2, IgG3, IgE and genotyping <italic>IL4</italic>-590, # = Chi-squared test was used to test the difference of <italic>IL4</italic>-590 CC+CT and TT distribution between the low and high 3 tiles. * = &#x003bc;g/ml, ** = ng/ml, A = number of patients who carry <italic>IL4</italic>-590 CC genotype, B = number of patients who carry <italic>IL4</italic>-590 CT genotype, C = number of patients who carry <italic>IL4</italic>-590 TT genotype, D = Number of patients who had low, middle and high anti-<italic>P. falciparum </italic>-IgG1, -IgG2, -IgG3 and IgE levels.</p></table-wrap-foot></table-wrap><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Association between <italic>IL4</italic>-590 genotype and anti-<italic>P. falciparum </italic>-IgG1 and -IgG3 levels base on previous experiences malaria infection in patients with complicated and uncomplicated malaria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th/><th align="center" colspan="8">Complicated malaria</th></tr><tr><th/><th/><th/><th colspan="8"><hr/></th></tr><tr><th/><th/><th/><th align="left" colspan="4">Without previous malaria experiences (76)<sup>a</sup></th><th align="left" colspan="4">With previous malaria experiences (27)</th></tr><tr><th/><th/><th/><th colspan="4"><hr/></th><th colspan="4"><hr/></th></tr><tr><th/><th align="left" colspan="2">3-tiles of Ig levels</th><th align="left">CC</th><th align="left">CT</th><th align="left">TT</th><th align="left"><italic>P</italic>-value<sup>#</sup></th><th align="left">CC</th><th align="left">CT</th><th align="left">TT</th><th align="left"><italic>P</italic>-value<sup>#</sup></th></tr><tr><th colspan="7"><hr/></th><th colspan="4"><hr/></th></tr><tr><th align="left">Anti-<italic>Pf</italic>IgG1*</th><th align="left">Low</th><th align="left">0-14.47</th><th align="left">0<sup>A</sup></th><th align="left">17<sup>B</sup></th><th align="left">21<sup>C</sup></th><th align="left">0.1373</th><th align="left">0</th><th align="left">3</th><th align="left">4</th><th align="left">0.7715</th></tr><tr><th/><th align="left">Medium</th><th align="left">14.76-106.1</th><th align="left">1</th><th align="left">11</th><th align="left">11</th><th/><th align="left">1</th><th align="left">4</th><th align="left">5</th><th/></tr><tr><th/><th align="left">High</th><th align="left">107.2-1874</th><th align="left">2</th><th align="left">5</th><th align="left">6</th><th/><th align="left">1</th><th align="left">4</th><th align="left">5</th><th/></tr><tr><th colspan="7"><hr/></th><th colspan="4"><hr/></th></tr><tr><th align="left">Anti-<italic>Pf</italic>IgG3*</th><th align="left">Low</th><th align="left">0.053-0.798</th><th align="left">0</th><th align="left">17</th><th align="left">23</th><th align="left">0.2136</th><th align="left">1</th><th align="left">2</th><th align="left">6</th><th align="left">0.0156</th></tr><tr><th/><th align="left">Medium</th><th align="left">0.854-3.55</th><th align="left">2</th><th align="left">10</th><th align="left">11</th><th/><th align="left">0</th><th align="left">2</th><th align="left">7</th><th/></tr><tr><th/><th align="left">High</th><th align="left">3.629-119</th><th align="left">1</th><th align="left">6</th><th align="left">4</th><th/><th align="left">1</th><th align="left">7</th><th align="left">1</th><th/></tr></thead><tbody><tr><td/><td/><td/><td align="center" colspan="8"><bold>Uncomplicated malaria</bold></td></tr><tr><td/><td/><td/><td colspan="8"><hr/></td></tr><tr><td/><td/><td/><td align="left" colspan="4"><bold>Without previous malaria experiences (74)</bold></td><td align="left" colspan="4"><bold>With previous malaria experiences (91)</bold></td></tr><tr><td/><td/><td/><td colspan="4"><hr/></td><td colspan="4"><hr/></td></tr><tr><td/><td/><td/><td align="left"><bold>CC</bold></td><td align="left"><bold>CT</bold></td><td align="left"><bold>TT</bold></td><td align="left"><bold><italic>P</italic>-value<sup>#</sup></bold></td><td align="left"><bold>CC</bold></td><td align="left"><bold>CT</bold></td><td align="left"><bold>TT</bold></td><td align="left"><bold><italic>P</italic>-value<sup>#</sup></bold></td></tr><tr><td colspan="7"><hr/></td><td colspan="4"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG1</td><td align="left">Low</td><td align="left">0-14.47</td><td align="left">0</td><td align="left">15</td><td align="left">11</td><td align="left">0.8019</td><td align="left"><bold>2</bold></td><td align="left"><bold>7</bold></td><td align="left"><bold>5</bold></td><td align="left"><bold>0.1219</bold></td></tr><tr><td/><td align="left">Medium</td><td align="left">14.76-106.1</td><td align="left">2</td><td align="left">9</td><td align="left">12</td><td/><td align="left">1</td><td align="left">11</td><td align="left">20</td><td/></tr><tr><td/><td align="left">High</td><td align="left">107.2-1874</td><td align="left">2</td><td align="left">11</td><td align="left">11</td><td/><td align="left"><bold>4</bold></td><td align="left"><bold>13</bold></td><td align="left"><bold>25</bold></td><td/></tr><tr><td colspan="7"><hr/></td><td colspan="4"><hr/></td></tr><tr><td align="left">Anti-<italic>Pf</italic>IgG3</td><td align="left">Low</td><td align="left">0.053-0.798</td><td align="left">1</td><td align="left">13</td><td align="left">12</td><td align="left">0.8772</td><td align="left"><bold>2</bold></td><td align="left"><bold>7</bold></td><td align="left"><bold>4</bold></td><td align="left"><bold>0.0206</bold></td></tr><tr><td/><td align="left">Medium</td><td align="left">0.854-3.55</td><td align="left">1</td><td align="left">10</td><td align="left">12</td><td/><td align="left">4</td><td align="left">11</td><td align="left">16</td><td/></tr><tr><td/><td align="left">High</td><td align="left">3.629-119</td><td align="left">2</td><td align="left">12</td><td align="left">11</td><td/><td align="left"><bold>1</bold></td><td align="left"><bold>14</bold></td><td align="left"><bold>30</bold></td><td/></tr></tbody></table><table-wrap-foot><p>a = Number of patients (in the parenthesis), # = Chi- squared test was used to test the difference of <italic>IL4</italic>-590 CC, CT and TT distribution between the low and high 3 tiles, * = &#x003bc;g/ml, A, B and C = number of patients with previous malaria experiences for determining anti-<italic>P. falciparum </italic>-IgG1, -IgG3 and carry <italic>IL4</italic>-590 CC, CT, TT genotypes, respectively.</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>This study demonstrated that <italic>IL4</italic>-590 genotypes could differently regulate anti-<italic>P. falciparum </italic>-IgG1 and -IgG3 responses. The association between individuals homozygous for <italic>IL4</italic>-590 T alleles and the levels of anti-<italic>P. falciparum </italic>IgG3 was found only in patients who had previous malaria experiences with low levels in complicated malaria and high levels in uncomplicated malaria. When the differences in antibody levels between genotypes were explored, similar results were seen for anti-<italic>P. falciparum </italic>IgG3 in that complicated malaria patients with previous malaria experiences tended to have lower IgG3 levels in those carrying TT compared to CT genotypes. In contrast, the complicated malaria patients without previous malaria experiences who carried CC genotype had significantly higher IgG1 than those carrying either CT or TT genotypes. Thus, repeated exposure and host genetics, <italic>i.e </italic>the polymorphism of <italic>IL4</italic>-590 or other related genes has an impact on the modulation of antibody isotype profiles and altered clinical outcome.</p><p>The relationship between <italic>IL4 </italic>polymorphism and anti-<italic>P. falciparum </italic>IgG subclasses antibody levels has not been studied thoroughly. This is the first finding to show that a single nucleotide polymorphism at position <italic>IL4</italic>-590 transition from C to T is associated with the levels of anti-<italic>P. falciparum </italic>IgG3 antibody in malaria patients. In complicated malaria especially those with previous malaria experiences, the levels of anti-<italic>P. falciparum </italic>IgG3 were significantly different among patients carrying <italic>IL4</italic>-590 CC, CT or TT genotypes. In particular, complicated malaria patients homozygous for <italic>IL4</italic>-590 T alleles and with previous malaria experiences exhibited significantly lower levels of anti-<italic>P. falciparum </italic>IgG3 antibody than their <italic>IL4</italic>-590 counterparts, whereas significantly higher levels were found in uncomplicated malaria patients homozygous for <italic>IL4</italic>-590 T alleles and with previous malaria experiences. Similar trends were observed for the anti-<italic>P. falciparum </italic>IgG1 in uncomplicated malaria patients with previous malaria experiences although this did not reach statistically significant differences. These results are consistent with the previous findings that low levels of IgG3 may lead to the onset of complicated malaria while high IgG3 antibody levels may protect against malaria [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>] and with the demonstration on the induction of CD40L stimulated na&#x000ef;ve B cells by IL4 alone or in combination with IL10 to express IgG1, IgG2 and IgG3, but little IgG4 [<xref ref-type="bibr" rid="B27">27</xref>]. IgG3 can activate the complement pathways [<xref ref-type="bibr" rid="B28">28</xref>] and co-operate through FcR receptors [<xref ref-type="bibr" rid="B29">29</xref>], thus, IgG3 could induce cell mediated lysis via complement pathways, phagocytosis and/or ADCI mechanism [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B30">30</xref>] which are all known to facilitate parasite clearance. In fact, IgG3 may involve in anti-disease immunity by neutralizing parasite toxin, the glycosylphosphatidylinositol (GPI) membrane anchors of <italic>P. falciparum </italic>surface proteins and/or inhibiting cytoadherence of infected red blood cells, thus, interfering the parasite sequestration [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. In humans, IL10, IL21 are associated with IgG1 and IgG3 antibody production [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B33">33</xref>] while IL-27 is modest and regulates exclusively the production of IgG1 [<xref ref-type="bibr" rid="B34">34</xref>]. Furthermore, the interaction and combination of different base changes at several sites in the promoter and/or the co-localized alleles of these cytokines and their signaling genes including the <italic>IL4</italic>-590 polymorphism may differ in patients with complicated and uncomplicated malaria and thus, alter the IgG1 and IgG3 production. This may also explain why different anti-<italic>P. falciparum </italic>IgG3 levels were observed only among patients with complicated malaria carrying <italic>IL4</italic>-590 TT genotype compared to their counterparts.</p><p>The present study did not reveal any association between <italic>IL4-</italic>590 C/T transition and the severity of malaria in either with or without previous malaria experiences, although there was an association between <italic>IL4-</italic>590 TT genotype and the levels of anti-<italic>P. falciparum </italic>IgG3 antibody in both complicated and uncomplicated malaria patients with previous malaria experiences. The reason for this discrepancy is probably due to: firstly, the polymorphism itself may not be functional but act as genetic markers of other functional polymorphisms; secondly, the polymorphisms may directly regulate IL4 production only in the presence of other genetic determinants. In contrast to the results recently demonstrated in Mali of West Africa. The <italic>IL4-</italic>590 T alleles were associated with the increased levels of both total and anti-malarial IgE in the Fulani, but not the Dogon. However, <italic>IL4-</italic>590 polymorphism did not influence on the levels of anti-malarial IgG1-3 subclasses in both the Fulani and the Dogon [<xref ref-type="bibr" rid="B35">35</xref>]. The reason for genetic disparities can be attributed to different ages, ethnicity, geographical differences, and clinical feature as asymptomatic and acute malaria infection.</p><p>The <italic>IL4</italic>-590 C or T alleles in association with primary and secondary anti-<italic>P. falciparum -</italic>IgG1 and -IgG3 responses were different. The <italic>IL4</italic>-590 T allele was associated with anti-<italic>P. falciparum </italic>IgG3 levels in which the low levels were observed in complicated and the high levels were observed in uncomplicated malaria with previous malaria experiences. In complicated malaria with previous malaria experiences, the anti-<italic>P. falciparum </italic>IgG3 levels tended to be lower in patients carrying TT than those carrying CT genotypes. Conversely, the <italic>IL4</italic>-590 T allele seems to be associated with high anti-<italic>P. falciparum </italic>IgG1 in only uncomplicated malaria patients with previous malaria experiences, whereas, complicated malaria patients without previous malaria experiences who carried CC genotype had significantly higher anti-<italic>P. falciparum </italic>IgG1 than those either with CT or TT genotypes. Therefore, it is likely that T allele associated with secondary malaria infection, while C allele associated with primary infection. The shift of Ig-isotypes from primary to secondary responses has been demonstrated in mouse models to be correlated with the levels of either Th1 or Th2 cytokines [<xref ref-type="bibr" rid="B17">17</xref>]. Th1 subset predominates in the non-specific primary response, whereas Th2 is the major activated pathway in the secondary specific response. As demonstrate earlier that the nuclear factor of activated T cells (NFAT) binding site at <italic>IL4</italic>-590 T creates a hair trigger for <italic>IL4 </italic>transcription, it is advantageous when a Th2 response is required, while <italic>IL4</italic>-590 C is favored when a Th1 response is required [<xref ref-type="bibr" rid="B36">36</xref>]. Therefore, the modulation of Th1 and Th2 cytokines productions could have the impact on antibody classes and subclasses productions. It is possible that <italic>IL4</italic>-590&#x000b0;C or T in combination with previous exposure to malaria antigens probably partly modify the antibody isotype profiles and thus represent a wide spectrum of clinical symptoms. However, some of these observations need to be confirmed in a larger sample size in order to correct the confounding factors, such as age, number of previous episodes and parasite-virulence.</p></sec><sec><title>Conclusion</title><p>This study showed that <italic>IL4</italic>-590 C or T is likely to play a modulating role in the regulation of antibody profiles in primary and secondary immune responses. The <italic>IL4</italic>-590 T allele participated in the regulation of anti-<italic>P. falciparum </italic>-IgG1 and -IgG3 in secondary infection, whereas <italic>IL4</italic>-590 C allele might participated in the regulation of anti-<italic>P. falciparum </italic>IgG1 in primary infection. In individuals carrying the <italic>IL4</italic>-590 TT genotype with previous malaria experiences, an increased risk of complicated malaria was associated with low anti-<italic>P. falciparum </italic>IgG3 antibody, whereas a lower risk was associated with high antibody levels. However, a panel of genetic variations in humoral immune responses and their related genes in larger sample size should be further investigated which may provide clue for better understanding in the alteration of disease severity.</p></sec><sec><title>List of abbreviations used</title><p>CM: complicated malaria patients; CME: complicated malaria patients with previous malaria experiences; CMN: complicated malaria patients without previous malaria experiences; UCM: uncomplicated malaria patients; UCME: uncomplicated malaria patients with previous malaria experiences; UCMN: uncomplicated malaria patients without previous malaria experiences.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SK and PT designed the study; PT prepared the blood samples, performed the <italic>IL4</italic>-590 genotyping and ELISA, collected clinical data, analysed statistics and drafted the manuscript; HP contributed to ELISA; MH assisted in <italic>IL4</italic>-590 genotyping; SK and MTB supervised the work, revised the manuscript and financed the research. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>We wish to acknowledge the contribution of Late Professor Sornchai Looareesuwan, Department of Clinical Tropical Medicine and the Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University in providing blood samples and clinical data and his staff for their assistance in blood collection. We thank all patients for their kind participation in the study and Margareta Hagstedt, Stockholm University for her technical assistance. This study was supported by The Royal Golden Jubilee Ph.D. Programme (5 MMU44A1), the Basic Research Grant for the Royal Golden Jubilee Ph.D. (BGJ4580004) of the Thailand Research Fund (TRF), the Swedish Foundation for International Cooperation in Research and Higher Education (STINT), the Swedish International Development Co-operation Agency (SIDA/SAREC), the BioMalPar EU, #LSHP-CT-2004, 503578, Faculty of Tropical Medicine, Mahidol University and the Faculty of Medicine, Srinakharinwirot University. The present study was approved by the Ethical Committee of Faculty of Tropical Medicine, Mahidol University.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Perlmann</surname><given-names>P</given-names></name><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Looareesuwan</surname><given-names>S</given-names></name><name><surname>Krudsood</surname><given-names>S</given-names></name><name><surname>Kano</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Brittenham</surname><given-names>G</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name><article-title>Contrasting functions of IgG and IgE antimalarial antibodies in uncomplicated and severe <italic>Plasmodium falciparum </italic>malaria</article-title><source>Am J Trop Med Hyg</source><year>2000</year><volume>62</volume><fpage>373</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">11037780</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Bouharoun-Tayoun</surname><given-names>H</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name><article-title><italic>Plasmodium falciparum </italic>malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity</article-title><source>Infect Immun</source><year>1992</year><volume>60</volume><fpage>1473</fpage><lpage>1481</lpage><pub-id pub-id-type="pmid">1548071</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Bereczky</surname><given-names>S</given-names></name><name><surname>Montgomery</surname><given-names>SM</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Rooth</surname><given-names>I</given-names></name><name><surname>Shaw</surname><given-names>MA</given-names></name><name><surname>Farnert</surname><given-names>A</given-names></name><article-title>Elevated anti-malarial IgE in asymptomatic individuals is associated with reduced risk for subsequent clinical malaria</article-title><source>Int J Parasitol</source><year>2004</year><volume>34</volume><fpage>935</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2004.04.007</pub-id><pub-id pub-id-type="pmid">15217732</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Cerutti</surname><given-names>A</given-names></name><name><surname>Zan</surname><given-names>H</given-names></name><name><surname>Schaffer</surname><given-names>A</given-names></name><name><surname>Bergsagel</surname><given-names>L</given-names></name><name><surname>Harindranath</surname><given-names>N</given-names></name><name><surname>Max</surname><given-names>EE</given-names></name><name><surname>Casali</surname><given-names>P</given-names></name><article-title>CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line</article-title><source>J Immunol</source><year>1998</year><volume>160</volume><fpage>2145</fpage><lpage>2157</lpage><pub-id pub-id-type="pmid">9498752</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Cerutti</surname><given-names>A</given-names></name><name><surname>Zan</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>EC</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Schattner</surname><given-names>EJ</given-names></name><name><surname>Schaffer</surname><given-names>A</given-names></name><name><surname>Casali</surname><given-names>P</given-names></name><article-title>Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>6594</fpage><lpage>6603</lpage><pub-id pub-id-type="pmid">12444172</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Fear</surname><given-names>DJ</given-names></name><name><surname>McCloskey</surname><given-names>N</given-names></name><name><surname>O'Connor</surname><given-names>B</given-names></name><name><surname>Felsenfeld</surname><given-names>G</given-names></name><name><surname>Gould</surname><given-names>HJ</given-names></name><article-title>Transcription of Ig germline genes in single human B cells and the role of cytokines in isotype determination</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>4529</fpage><lpage>4538</lpage><pub-id pub-id-type="pmid">15383585</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Malisan</surname><given-names>F</given-names></name><name><surname>Briere</surname><given-names>F</given-names></name><name><surname>Bridon</surname><given-names>JM</given-names></name><name><surname>Harindranath</surname><given-names>N</given-names></name><name><surname>Mills</surname><given-names>FC</given-names></name><name><surname>Max</surname><given-names>EE</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Martinez-Valdez</surname><given-names>H</given-names></name><article-title>Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes</article-title><source>J Exp Med</source><year>1996</year><volume>183</volume><fpage>937</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1084/jem.183.3.937</pub-id><pub-id pub-id-type="pmid">8642297</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Fujieda</surname><given-names>S</given-names></name><name><surname>Saxon</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><article-title>Direct evidence that gamma 1 and gamma 3 switching in human B cells is interleukin-10 dependent</article-title><source>Mol Immunol</source><year>1996</year><volume>33</volume><fpage>1335</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1016/S0161-5890(96)00092-2</pub-id><pub-id pub-id-type="pmid">9171893</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Jeannin</surname><given-names>P</given-names></name><name><surname>Lecoanet</surname><given-names>S</given-names></name><name><surname>Delneste</surname><given-names>Y</given-names></name><name><surname>Gauchat</surname><given-names>JF</given-names></name><name><surname>Bonnefoy</surname><given-names>JY</given-names></name><article-title>IgE versus IgG4 production can be differentially regulated by IL-10</article-title><source>J Immunol</source><year>1998</year><volume>160</volume><fpage>3555</fpage><lpage>3561</lpage><pub-id pub-id-type="pmid">9531318</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Noma</surname><given-names>T</given-names></name><name><surname>Yata</surname><given-names>J</given-names></name><article-title>Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2</article-title><source>J Immunol</source><year>1994</year><volume>153</volume><fpage>4948</fpage><lpage>4958</lpage><pub-id pub-id-type="pmid">7963558</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Inoue</surname><given-names>R</given-names></name><name><surname>Kasahara</surname><given-names>K</given-names></name><name><surname>Fukao</surname><given-names>T</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Tashita</surname><given-names>H</given-names></name><name><surname>Teramoto</surname><given-names>T</given-names></name><article-title>Reduced expression of the interferon-gamma messenger RNA in IgG2 deficiency</article-title><source>Scand J Immunol</source><year>1997</year><volume>45</volume><fpage>227</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3083.1997.d01-387.x</pub-id><pub-id pub-id-type="pmid">9042436</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Rosenwasser</surname><given-names>LJ</given-names></name><name><surname>Klemm</surname><given-names>DJ</given-names></name><name><surname>Dresback</surname><given-names>JK</given-names></name><name><surname>Inamura</surname><given-names>H</given-names></name><name><surname>Mascali</surname><given-names>JJ</given-names></name><name><surname>Klinnert</surname><given-names>M</given-names></name><name><surname>Borish</surname><given-names>L</given-names></name><article-title>Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy</article-title><source>Clin Exp Allergy</source><year>1995</year><volume>25</volume><issue>Suppl 2</issue><fpage>74</fpage><lpage>78</lpage><comment>discussion 95-76</comment><pub-id pub-id-type="doi">10.1111/j.1365-2222.1995.tb00428.x</pub-id><pub-id pub-id-type="pmid">8590350</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Nakashima</surname><given-names>H</given-names></name><name><surname>Miyake</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Akahoshi</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Otsuka</surname><given-names>T</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><article-title>Association between IL-4 genotype and IL-4 production in the Japanese population</article-title><source>Genes Immun</source><year>2002</year><volume>3</volume><fpage>107</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/sj.gene.6363830</pub-id><pub-id pub-id-type="pmid">11960309</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Verra</surname><given-names>F</given-names></name><name><surname>Arca</surname><given-names>B</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><name><surname>Modiano</surname><given-names>D</given-names></name><article-title>Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa</article-title><source>Genes Immun</source><year>2001</year><volume>2</volume><fpage>411</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/sj.gene.6363797</pub-id><pub-id pub-id-type="pmid">11704810</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Verra</surname><given-names>F</given-names></name><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Calissano</surname><given-names>C</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Perlmann</surname><given-names>P</given-names></name><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Arca</surname><given-names>B</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Konate</surname><given-names>A</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><name><surname>Modiano</surname><given-names>D</given-names></name><article-title>IL4-589C/T polymorphism and IgE levels in severe malaria</article-title><source>Acta Trop</source><year>2004</year><volume>90</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2003.11.014</pub-id><pub-id pub-id-type="pmid">15177147</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Gyan</surname><given-names>BA</given-names></name><name><surname>Goka</surname><given-names>B</given-names></name><name><surname>Cvetkovic</surname><given-names>JT</given-names></name><name><surname>Kurtzhals</surname><given-names>JL</given-names></name><name><surname>Adabayeri</surname><given-names>V</given-names></name><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Lefvert</surname><given-names>AK</given-names></name><name><surname>Akanmori</surname><given-names>BD</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><article-title>Allelic polymorphisms in the repeat and promoter regions of the interleukin-4 gene and malaria severity in Ghanaian children</article-title><source>Clin Exp Immunol</source><year>2004</year><volume>138</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2004.02590.x</pub-id><pub-id pub-id-type="pmid">15373917</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>D'Imperio Lima</surname><given-names>MR</given-names></name><name><surname>Alvarez</surname><given-names>JM</given-names></name><name><surname>Furtado</surname><given-names>GC</given-names></name><name><surname>Kipnis</surname><given-names>TL</given-names></name><name><surname>Coutinho</surname><given-names>A</given-names></name><name><surname>Minoprio</surname><given-names>P</given-names></name><article-title>Ig-isotype patterns of primary and secondary B cell responses to <italic>Plasmodium chabaudi chabaudi </italic>correlate with IFN-gamma and IL-4 cytokine production with CD45RB expression by CD4+ spleen cells</article-title><source>Scand J Immunol</source><year>1996</year><volume>43</volume><fpage>263</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">8602459</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Tangteerawatana</surname><given-names>P</given-names></name><name><surname>Pichyangkul</surname><given-names>S</given-names></name><name><surname>Hayano</surname><given-names>M</given-names></name><name><surname>Kalambaheti</surname><given-names>T</given-names></name><name><surname>Looareesuwan</surname><given-names>S</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Khusmith</surname><given-names>S</given-names></name><article-title>Relative levels of IL4 and IFN-gamma in complicated malaria: association with IL4 polymorphism and peripheral parasitemia</article-title><source>Acta Trop</source><year>2007</year><volume>101</volume><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2007.02.008</pub-id><pub-id pub-id-type="pmid">17379175</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Tangteerawatana</surname><given-names>P</given-names></name><name><surname>Montgomery</surname><given-names>SM</given-names></name><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Looareesuwan</surname><given-names>S</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Khusmith</surname><given-names>S</given-names></name><article-title>Differential regulation of IgG subclasses and IgE antimalarial antibody responses in complicated and uncomplicated <italic>Plasmodium falciparum </italic>malaria</article-title><source>Parasite Immunol</source><year>2007</year><volume>29</volume><fpage>475</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.2007.00965.x</pub-id><pub-id pub-id-type="pmid">17727571</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Singhasivanon</surname><given-names>P</given-names></name><name><surname>Kidson</surname><given-names>C</given-names></name><name><surname>Supavej</surname><given-names>S</given-names></name><collab>eds</collab><article-title>Mekong Malaria II: update of malaria, multi-drug resistance and economic development in the Mekong region of Southeast Asia</article-title><source>Southeast Asia J Trop Med and Pub Health</source><year>2003</year><volume>34</volume><issue>suppl 4</issue><fpage>63</fpage><lpage>68</lpage></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><collab>World Health Organization</collab><article-title>Severe and complicated malaria</article-title><source>Trans R Soc Trop Med Hyg</source><year>2000</year><volume>94</volume><issue>Suppl</issue><fpage>51</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">10748898</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Patarroyo</surname><given-names>M</given-names></name><name><surname>Perlmann</surname><given-names>P</given-names></name><article-title>Regulation of the immune response in <italic>Plasmodium falciparum </italic>malaria. II. Antigen specific proliferative responses in vitro</article-title><source>Clin Exp Immunol</source><year>1983</year><volume>53</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">6192953</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Helmby</surname><given-names>H</given-names></name><name><surname>Hagstedt</surname><given-names>M</given-names></name><name><surname>Carlson</surname><given-names>J</given-names></name><name><surname>Larsson</surname><given-names>P</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Perlmann</surname><given-names>P</given-names></name><article-title>IgE anti-malarial antibodies in <italic>Plasmodium falciparum </italic>malaria: association of high IgE levels with cerebral malaria</article-title><source>Clin Exp Immunol</source><year>1994</year><volume>97</volume><fpage>284</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">8050178</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Alloueche</surname><given-names>A</given-names></name><name><surname>Silveira</surname><given-names>H</given-names></name><name><surname>Conway</surname><given-names>DJ</given-names></name><name><surname>Bojang</surname><given-names>K</given-names></name><name><surname>Doherty</surname><given-names>T</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Pinder</surname><given-names>M</given-names></name><name><surname>Greenwood</surname><given-names>BM</given-names></name><article-title>High-throughput sequence typing of T-cell epitope polymorphisms in <italic>Plasmodium falciparum </italic>circumsporozoite protein</article-title><source>Mol Biochem Parasitol</source><year>2000</year><volume>106</volume><fpage>273</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/S0166-6851(99)00221-2</pub-id><pub-id pub-id-type="pmid">10699256</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Metzger</surname><given-names>WG</given-names></name><name><surname>Okenu</surname><given-names>DM</given-names></name><name><surname>Cavanagh</surname><given-names>DR</given-names></name><name><surname>Robinson</surname><given-names>JV</given-names></name><name><surname>Bojang</surname><given-names>KA</given-names></name><name><surname>Weiss</surname><given-names>HA</given-names></name><name><surname>McBride</surname><given-names>JS</given-names></name><name><surname>Greenwood</surname><given-names>BM</given-names></name><name><surname>Conway</surname><given-names>DJ</given-names></name><article-title>Serum IgG3 to the <italic>Plasmodium falciparum </italic>merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria</article-title><source>Parasite Immunol</source><year>2003</year><volume>25</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3024.2003.00636.x</pub-id><pub-id pub-id-type="pmid">14507328</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Sarthou</surname><given-names>JL</given-names></name><name><surname>Angel</surname><given-names>G</given-names></name><name><surname>Aribot</surname><given-names>G</given-names></name><name><surname>Rogier</surname><given-names>C</given-names></name><name><surname>Dieye</surname><given-names>A</given-names></name><name><surname>Toure Balde</surname><given-names>A</given-names></name><name><surname>Diatta</surname><given-names>B</given-names></name><name><surname>Seignot</surname><given-names>P</given-names></name><name><surname>Roussilhon</surname><given-names>C</given-names></name><article-title>Prognostic value of anti-<italic>Plasmodium falciparum</italic>-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria</article-title><source>Infect Immun</source><year>1997</year><volume>65</volume><fpage>3271</fpage><lpage>3276</lpage><pub-id pub-id-type="pmid">9234786</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Ferguson</surname><given-names>A</given-names></name><name><surname>Avery</surname><given-names>DT</given-names></name><name><surname>Ma</surname><given-names>CS</given-names></name><name><surname>Hodgkin</surname><given-names>PD</given-names></name><article-title>Isotype switching by human B cells is division-associated and regulated by cytokines</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>4298</fpage><lpage>4306</lpage><pub-id pub-id-type="pmid">12370361</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Gregory</surname><given-names>L</given-names></name><name><surname>Jefferis</surname><given-names>R</given-names></name><article-title>Aspects of the molecular structure of IgG subclasses</article-title><source>Monogr Allergy</source><year>1986</year><volume>19</volume><fpage>7</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">2945094</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Groux</surname><given-names>H</given-names></name><name><surname>Gysin</surname><given-names>J</given-names></name><article-title>Opsonization as an effector mechanism in human protection against asexual blood stages of <italic>Plasmodium falciparum</italic>: functional role of IgG subclasses</article-title><source>Res Immunol</source><year>1990</year><volume>141</volume><fpage>529</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/0923-2494(90)90021-P</pub-id><pub-id pub-id-type="pmid">1704637</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Tebo</surname><given-names>AE</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Luty</surname><given-names>AJ</given-names></name><article-title><italic>Plasmodium falciparum</italic>: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro</article-title><source>Exp Parasitol</source><year>2001</year><volume>98</volume><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1006/expr.2001.4619</pub-id><pub-id pub-id-type="pmid">11426948</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Boutlis</surname><given-names>CS</given-names></name><name><surname>Fagan</surname><given-names>PK</given-names></name><name><surname>Gowda</surname><given-names>DC</given-names></name><name><surname>Lagog</surname><given-names>M</given-names></name><name><surname>Mgone</surname><given-names>CS</given-names></name><name><surname>Bockarie</surname><given-names>MJ</given-names></name><name><surname>Anstey</surname><given-names>NM</given-names></name><article-title>Immunoglobulin G (IgG) responses to <italic>Plasmodium falciparum </italic>glycosylphosphatidylinositols are short-lived and predominantly of the IgG3 subclass</article-title><source>J Infect Dis</source><year>2003</year><volume>187</volume><fpage>862</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1086/367897</pub-id><pub-id pub-id-type="pmid">12599061</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Schofield</surname><given-names>L</given-names></name><name><surname>Mueller</surname><given-names>I</given-names></name><article-title>Clinical immunity to malaria</article-title><source>Curr Mol Med</source><year>2006</year><volume>6</volume><fpage>205</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.2174/156652406776055221</pub-id><pub-id pub-id-type="pmid">16515511</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Mewono</surname><given-names>L</given-names></name><name><surname>Matondo Maya</surname><given-names>DW</given-names></name><name><surname>Matsiegui</surname><given-names>PB</given-names></name><name><surname>Agnandji</surname><given-names>ST</given-names></name><name><surname>Kendjo</surname><given-names>E</given-names></name><name><surname>Barondi</surname><given-names>F</given-names></name><name><surname>Issifou</surname><given-names>S</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Mavoungou</surname><given-names>E</given-names></name><article-title>Interleukin-21 is associated with IgG1 and IgG3 antibodies to erythrocyte-binding antigen-175 peptide 4 of <italic>Plasmodium falciparum </italic>in Gabonese children with acute falciparum malaria</article-title><source>Eur Cytokine Netw</source><year>2008</year><volume>19</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">18299268</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Boumendjel</surname><given-names>A</given-names></name><name><surname>Tawk</surname><given-names>L</given-names></name><name><surname>Malefijt</surname><given-names>RW</given-names></name><name><surname>Boulay</surname><given-names>V</given-names></name><name><surname>Yssel</surname><given-names>H</given-names></name><name><surname>Pene</surname><given-names>J</given-names></name><article-title>IL-27 induces the production of IgG1 by human B cells</article-title><source>Eur Cytokine Netw</source><year>2006</year><volume>17</volume><fpage>281</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">17353163</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Vafa</surname><given-names>M</given-names></name><name><surname>Maiga</surname><given-names>B</given-names></name><name><surname>Israelsson</surname><given-names>E</given-names></name><name><surname>Dolo</surname><given-names>A</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><article-title>Impact of the IL-4 -590 C/T transition on the levels of <italic>Plasmodium falciparum </italic>specific IgE, IgG, IgG subclasses and total IgE in two sympatric ethnic groups living in Mali</article-title><source>Microbes Infect</source><year>2009</year><volume>11</volume><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">19409508</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Rockman</surname><given-names>MV</given-names></name><name><surname>Hahn</surname><given-names>MW</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Goldstein</surname><given-names>DB</given-names></name><name><surname>Wray</surname><given-names>GA</given-names></name><article-title>Positive selection on a human- specific transcription factor binding site regulating IL4 expression</article-title><source>Curr Biol</source><year>2003</year><volume>13</volume><fpage>2118</fpage><lpage>2123</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2003.11.025</pub-id><pub-id pub-id-type="pmid">14654003</pub-id></mixed-citation></ref></ref-list></back></article>